Literature DB >> 7752031

Downgaze restriction after placement of superior oblique tendon spacer for Brown syndrome.

M E Wilson1, R B Sinatra, R A Saunders.   

Abstract

Diplopia in the reading position developed in two patients with unilateral Brown syndrome after a 7-millimeter section of #240 silicone retinal band was sewn between the cut ends of the superior oblique tendon at tenotomy. In both cases, forced ductions were positive, indicating a restrictive downgaze deficit. Surgical exploration revealed adhesions that prevented the normal sliding of the superior oblique tendon beneath the superior rectus muscle. Forced ductions became normal and downgaze improved after removal of the silicone band. Secondary superior oblique muscle paresis was also evident at the time of reoperation, requiring recession of the contralateral inferior rectus muscle (cases 1 and 2) and recession of the ipsilateral inferior oblique muscle (case 1). A restrictive downgaze deficit and a paretic overcorrection must be recognized as possible complications of the superior oblique tendon silicone "expander" operation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7752031     DOI: 10.3928/0191-3913-19950101-08

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  4 in total

1.  Achieving success with the silicone expander for overacting superior obliques.

Authors:  Z F Pollard; M Greenberg
Journal:  Trans Am Ophthalmol Soc       Date:  1999

2.  Brown's syndrome: diagnosis and management.

Authors:  K W Wright
Journal:  Trans Am Ophthalmol Soc       Date:  1999

3.  Surgical outcomes in correction of Brown syndrome.

Authors:  Yoonae A Cho; Soo Kim; Michael H Graef
Journal:  Korean J Ophthalmol       Date:  2006-03

4.  Combined Brown syndrome and superior oblique palsy without a trochlear nerve: case report.

Authors:  Hee Kyung Yang; Jae Hyoung Kim; Ji-Soo Kim; Jeong-Min Hwang
Journal:  BMC Ophthalmol       Date:  2017-08-25       Impact factor: 2.209

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.